Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Technology / Melanoma Vaccine Reduces Recurrence by 49%
Tech medical breakthrough

Melanoma Vaccine Reduces Recurrence by 49%

Analysis based on 7 articles · First reported Jun 01, 2026 · Last updated Jun 01, 2026

Sentiment
80
Attention
6
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The positive results of the intismeran and pembrolizumab combination therapy are expected to significantly boost the stock prices of Moderna>>> and Merck & Co.>>> due to the potential for increased sales and market expansion in cancer treatment. This breakthrough could also lead to increased investment and innovation across the biotechnology and pharmaceutical sectors, particularly in mRNA vaccine technology and immunotherapy.

Pharmaceuticals Biotechnology Healthcare
Event Summary

A new study led by NYU Langone Health has shown that a combination therapy of the personalized mRNA vaccine intismeran (manufactured by Moderna>>>) and the immunotherapy drug pembrolizumab (Keytruda, manufactured by Merck & Co.>>>) significantly reduces the risk of melanoma recurrence and death by 49% after five years. The phase 2b trial, KEYNOTE-942, involved 157 patients in the United States>>> and Australia>>> and demonstrated that 68.8% of patients receiving the combination therapy remained cancer-free, compared to 49.1% in the pembrolizumab-alone group. The therapy also reduced the risk of distant metastasis by 59%. Janice Mehnert>>>, the study's senior investigator, highlighted the potential for mRNA vaccines in treating other cancers. The findings are being presented at the 2026 annual meeting of the American Society of Clinical Oncology>>>.

Key Actions
90 Janice Mehnert presented results American Society of Clinical Oncology
Entities Involved
stock
Moderna
As the manufacturer of intismeran, Moderna>>> is a key beneficiary of the positive clinical trial results, which could lead to increased revenue and market share in cancer treatment. The success of intismeran validates Moderna>>>'s mRNA vaccine platform for oncology applications.
Importance 90 Sentiment 70
per
Janice Mehnert
Janice Mehnert>>> is the study's senior investigator, gaining significant recognition and enhancing her professional standing in the medical community due to the groundbreaking results. Her leadership is crucial to the success and dissemination of these findings.
Importance 90 Sentiment 70
stock
Merck & Co.
As the manufacturer of pembrolizumab (Keytruda), Merck & Co.>>> benefits from the combination therapy's success, as it reinforces the drug's role as a standard of care and expands its potential market in combination with intismeran. The positive results could lead to continued strong sales for pembrolizumab.
Importance 80 Sentiment 60
ngo
American Society of Clinical Oncology
The American Society of Clinical Oncology>>> is hosting the presentation of the trial results, solidifying its role as a central platform for disseminating significant cancer research. This event enhances its prestige and influence within the oncology community.
Importance 40 Sentiment 50
ngo
Cancer Research UK
Cancer Research UK>>> welcomed the findings, reinforcing its mission to support cancer research and providing a positive endorsement of the vaccine's potential. Its statement helps raise public awareness and encourages further research.
Importance 30 Sentiment 50
cnt
Australia
Australia>>> is one of the countries where patients were enrolled for the KEYNOTE-942 trial, contributing to the global scope of the research. Its involvement highlights its participation in international medical studies.
Importance 10 Sentiment 20
cnt
United States
United States>>> is one of the countries where patients were enrolled for the KEYNOTE-942 trial, contributing to the global scope of the research. Its involvement highlights its participation in international medical studies and its significant burden of skin cancer cases.
Importance 10 Sentiment 20
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.